当前位置: 首页 > 期刊 > 《中外医疗》 > 2014年第6期
编号:13138054
CHADS2评分与CHA2DS2—VASC评分孰优孰劣(4)
http://www.100md.com 2014年2月25日 《中外医疗》 2014年第6期
     [14] Camm AJ, Lip GY, De Caterina R,et al. 2012focused update of the ESC guidelines for the management of atrial fibrillation:an update of the 2010 ESC guidelines for the management of atrial fibrillation .Developed with the special contribution of the European Heart Rhythm Association[J].Eur Heart J,2012,33:2719-2747.

    [15] Olesen JB,Lip GY,Hansen ML,et al.Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nation wide cohort study[J].BMJ,2011,342:dl124.

    [16] 孟祥亚.CHA2DS2-VASc评分法在房颤患者卒中风险评估的应用 价值[J].中国医疗前沿,2012,7(18):17,30.

    [17] European Heart Rhythm Association. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC)[J].Eur Heart J,2010,31(19):2369-2429.

    [18] Skanes AC,Healey JS,Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control[J].Can J Cardiol,2012,28(2):125 -136.

    [19] You JJ,Singer DE,Howard PA, et al. Anti-thrombotic therapy for at- rial fibrillation: Anti-thrombotic Therapy and Prevention of Thrombosis,9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl):e531S -575S.

    (收稿日期:2013-12-30), 百拇医药(刘骅 刘启明)
上一页1 2 3 4